retatrutide ly3437943 triple agonist gip glp-1 glucagon LY3437943, a novel GIP, GLP-1, and receptor in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial retatrutide ly3437943 triple agonist gip

Traditional aesthetic approaches often focus on surface correction, while regenerative peptide therapy may support the biological processes that influence how your skin renews itself over time

Apply a cold pack to your forehead or neck to soothe pain

What we put in our body and how we treat our body plays a critical role in how much glutathione our body is able to produce and maintain at a given time

An analysis of 76 trials found CagriSema outperformed tirzepatide for weight loss

Each subject received their assigned capsules in identical packages at weeks 0, 4, and 8, with 30 capsules per visit (two extra capsules per package)